Clinical Trials Logo

Clinical Trial Summary

This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with sorafenib versus treatment with sorafenib alone in subjects with metastatic hepatocellular carcinoma. The phase I aspect will assess the safety and efficacy of the concurrent treatments and the phase II aspect will utilize CT (computer-tomography) scans to assess overall tumor response rate and evaluate disease progression


Clinical Trial Description

Intravenous Ascorbic Acid (Vitamin C) is a widely used alternative cancer treatment. This trial will study an intravenous Vitamin C treatment for persons with liver cancer that has spread, who are also receiving Sorafenib (a standard cancer drug), to see whether the combination of Vitamin C and Sorafenib is safe and well tolerated. Phase I will involve 6 persons who will receive the Vitamin C for 8 weeks to more specifically assess the safety of getting Vitamin C in combination with Sorafenib. Phase II will be randomized to receive either Vitamin C plus Sorafenib or Sorafenib alone for 16 weeks. If Vitamin C has a beneficial effect on tumour cells, patients may experience a regression of tumor or tumor markers. Additional benefits include scans at no charge to the patient. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01754987
Study type Interventional
Source Thomas Jefferson University
Contact
Status Completed
Phase Phase 1/Phase 2
Start date September 2012
Completion date January 2016

See also
  Status Clinical Trial Phase
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Recruiting NCT00752063 - Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma Phase 2
Terminated NCT03695250 - BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer Phase 1/Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Recruiting NCT05075993 - Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors Phase 1
Recruiting NCT04828486 - Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer Phase 2
Recruiting NCT05168163 - Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer Phase 2
Completed NCT03893695 - Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) Phase 1/Phase 2
Not yet recruiting NCT06427941 - A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04175912 - Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Phase 2
Withdrawn NCT04025567 - Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral Phase 2
Recruiting NCT03937830 - Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma Phase 2
Not yet recruiting NCT06066138 - A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing Phase 1
Recruiting NCT05199285 - A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Phase 2
Recruiting NCT05003895 - GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC) Phase 1
Recruiting NCT04511455 - Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment Phase 2
Withdrawn NCT06006286 - A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04221893 - Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers N/A
Recruiting NCT05092373 - Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Phase 1